2018 Annual Sessions

OS37 - ORAL SESSION 37 - New Treatment Paradigms in Pulmonary Hypertension

Apr 13, 2018 4:30pm ‐ Apr 13, 2018 6:00pm


Description

(365)  Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function
Raymond Benza, MD

(366)  Rates of Hospitalization Associated with the Use of Aldosterone Receptor Antagonists in Patients with Pulmonary Arterial Hypertension
Morgan Corkish, PharmD

(367)  OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs)
Ashwin Ra
vichandran,  MD, MPH, FACC

(369)  Intravenous Treprostinil Delivered by Implantable Pump for the Treatment of Pulmonary Arterial Hypertension - Report of First 11 Cases
Dror Rosengarten, MD

(370)  LVAD Does Not Improve Outcomes in Patients with Pulmonary Hypertension after Heart Transplantation
Chase Brown, MD

Speaker(s):

Tags: MCS PHARM

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content